読み込み中
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
前日終値
$10.30
−$0.02 · -0.19%
日中の時刻はETです。市場データは遅延する場合があります。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日中レンジ
現在 $10.30
52週レンジ
現在 $10.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
75
割安
センチメント
68
強気
リスク
51
やや高いリスク
モメンタム
89
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日中レンジ
現在 $10.30
52週レンジ
現在 $10.30
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.24億 USD | 7562.2万 USD | — | — | — |
| 売上原価 | 835.6万 USD | 812.1万 USD | 622.2万 USD | — | — |
| 粗利益 | 1.15億 USD | 6750.1万 USD | −622.2万 USD | — | — |
| 研究開発 | 1.42億 USD | 1.22億 USD | 1.05億 USD | 8506.1万 USD | 5715.5万 USD |
| 販売・一般管理 | 3638万 USD | 3517.1万 USD | 3203.9万 USD | 2732.3万 USD | 1572.7万 USD |
| 営業費用 | 1.7億 USD | 1.49億 USD | 1.37億 USD | 1.12億 USD | 7288.2万 USD |
| 受取利息 | 1294.2万 USD | 1056.6万 USD | 933.4万 USD | 376.4万 USD | 4.6万 USD |
| 支払利息 | — | — | — | 376.4万 USD | — |
| 減価償却費と償却費 | 835.6万 USD | 812.1万 USD | 622.2万 USD | 374.5万 USD | 213.2万 USD |
| 営業利益 | −5420.8万 USD | −8111.2万 USD | −1.43億 USD | −1.12億 USD | −7288.2万 USD |
| 純利益 | −3862.6万 USD | −7270万 USD | −1.35億 USD | −1.09億 USD | −7395.8万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3570.54万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2202.26万0.22%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM2012.23万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1105.49万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO707.81万0.05%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO593万0.03%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS555.51万0.02%338.69億 USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB474.14万0.05%108.2億 USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
